Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Lignende værker

• Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
  af: Taher, Ali T, et al.
  Udgivet: (2014)
• Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
  af: Taher, Ali T, et al.
  Udgivet: (2013)
• Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
  af: Taher, Ali T., et al.
  Udgivet: (2013)
• Changing patterns in the epidemiology of β‐thalassemia
  af: Kattamis, Antonis, et al.
  Udgivet: (2020)
• Does Splenectomy Influence the Development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A Retrospective Study
  af: Skafida, Myrto, et al.
  Udgivet: (2019)